Next year expected since the beginning of the year 2011 also the private health insurance benefit contribution stabilization of considerable price advantages in drugs. The change in the law was possible to the restructuring of the pharmaceutical market (AMNOG). The insurance Portal reported private-krankenversicherung.de, which plans track the private insurers, and when a discharge is expected. The costs for medicines may increase even at relatively small complaints to unimagined heights. In the future, drug rebates are supposed to benefit also the private health insurance companies. It is expected to cost savings of 300 million euros. The insurers are benefiting in the long term the insured should required to use these funds, to stabilise the premiums. Already from the second quarter of 2011 the central point should be active to the payroll of drug discounts, short ZESAR.
The Mission of the society, which was founded by the Association of private health insurance and aid media, is the central management the payment operations. This discounts directly with pharmaceutical manufacturers should be billed. Privately, continue to pay the price of medicine in the Pharmacy and later get back the cost of their insurance. In the background the ZESAR cares but the claim of the price advantages. After the revenue directly to the insurer and aid bodies are, ultimately the policyholders benefit. More information: news.private-krankenversicherung.de/… Learn more on the subject from Nike. GELD.